|
|
Article: Boehringer Ingelheim and Genentech Announce Initiation of a Clinical Trial Evaluating TNKase/Metalyse Use Prior to Angioplasty for Treatment of Heart Attack.
- Article from:
- Business Wire
- Article date:
- November 11, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
BIOWIRE2K
ORLANDO, Fla.--(BUSINESS WIRE)--Nov. 11, 2003
International Study Seeks to Determine Efficacy of a Combined
Medical/Mechanical Approach in Improving Survival and Clinical
Outcomes in Acute MI
Boehringer Ingelheim and Genentech, Inc., today announced that they plan to test the single-bolus thrombolytic TNKase(TM)/Metalyse(R) (Tenecteplase) in combination with percutaneous coronary intervention (PCI, also known as primary angioplasty) as a potential treatment regimen for acute myocardial infarction (AMI).